HomeAI · summaries
Storia in 3 fonti
Crystalys gets $130M to take Sobi-rivaling gout drug to market
Crystalys Therapeutics raises $130M Series B, led by Frazier Life Sciences, to bring gout drug dotinurad to US/EU markets. The drug is already approved in Japan, China.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Crystalys nets $130M more to push gout drug through late-stage tests
The startup has a broad global development program underway — and the support of more than 20 investment firms — for a treatment that’s approved in many Asian countries but isn’t…
- ·
endpoints.news
Crystalys gets $130M to take Sobi-rivaling gout drug to market
Crystalys Therapeutics raises $130M Series B, led by Frazier Life Sciences, to bring gout drug dotinurad to US/EU markets. The drug is already approved in Japan, China.
